Clinical Trials Sponsored by Biogen Idec

Total 2134 results

Biogen

Completed

A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function (TRUST)

Relapsing-Remitting Multiple Sclerosis
Biogen

Completed

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS) (JEMS)

Multiple Sclerosis
Biogen

Completed

A Single-Dose, Pharmacokinetic/Pharmacodynamic (PK/PD), & Safety Study of BIIB017 in Participants With Renal Impairment & Healthy Volunteers

Healthy | Renal Insufficiency
Biogen

Completed

PeptoBismol® Use to Reduce Gastrointestinal Events in Healthy Volunteers Receiving DMF [Tecfidera®] Twice Daily

Healthy

United States
Biogen

Completed

Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta (RENeu)

Relapsing-Remitting Multiple Sclerosis

New Zealand, Australia
Biogen

Completed

Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS) (Avonex China)

Multiple Sclerosis

China
Biogen

Completed

Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS

Relapsing-remitting Multiple Sclerosis

Belgium, Denmark, Finland, Netherlands, Norway, Sweden, Switzerland, United Kingdom
Biogen

Completed

MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia (MATRIX)

Multiple Sclerosis

Colombia, Mexico
Biogen

Completed

Effect of Food and Antacid on BIIB021 With Advanced Solid Tumors

Advanced Solid Tumors

United States
Biogen

Completed

Study in Healthy Volunteers to Establish the Bioequivalence of Two Different Manufacturers.

Healthy Volunteers

United States
Biogen

Terminated

Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma

Colorectal Cancer | Metastases

United States
Biogen

Completed

Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis (PROOF)

Multiple Sclerosis

United States, Australia, Austria, Canada
Biogen

Completed

Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's Disease

Parkinson's Disease

United Kingdom, Israel, India
Biogen

Completed

GER-009-06-AVX Early Therapy in Multiple Sclerosis (FIT)

Relapsing-Remitting Multiple Sclerosis
Biogen

Completed

Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe

Multiple Sclerosis
Biogen

Completed

A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers

Multiple Sclerosis
Biogen

Completed

Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a? (FLAIR)

Relapsing Remitting Multiple Sclerosis

Belgium, Luxembourg, United Kingdom
Biogen

Terminated

Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United States
Biogen

Completed

Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)

Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma

United States, Canada
IDEA AG

Completed

IDEA-033 Three Months Dose Finding in OA Followed by IDEA-033 Three Months Extension in OA

Osteoarthritis; Knee
IDEA AG

Completed

Ketoprofen in Transfersome Compared to Oral Celecoxib and Placebo for Pain Associated With Osteoarthritis of the Knee

Osteoarthritis, Knee
IDEA AG

Completed

Multiple Dose, Double-Blind, Placebo and Active Controlled Study of Pharmacokinetics of Diractin® as Well as Safety and Efficacy for the Treatment of Muscle Soreness

Muscle Soreness

Germany
IDEA AG

Completed

An Effectiveness and Safety Study of IDEA-033 in Comparison to Oral Naproxen and Placebo for the Treatment of Osteoarthritis of the Knee

Osteoarthritis, Knee

United States
IDEA AG

Completed

A Long-Term Safety Study of IDEA-033 in Comparison to Oral Naproxen for the Treatment of Osteoarthritis of the Knee

Osteoarthritis, Knee

United States
Biogen

Recruiting

A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments

Multiple Sclerosis, Relapsing-Remitting

United States
Biogen

Not yet recruiting

A Study of Omaveloxolone in Children With Friedreich's Ataxia

Friedreich Ataxia

United States
Biogen

Recruiting

A Study of Spinraza (Nusinersen) Exposure in Pregnant Women With Spinal Muscular Atrophy (SMA) Within Existing SMA Registries

Muscular Atrophy, Spinal

United States
Biogen

Recruiting

A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants (SATURATE-MS)

Multiple Sclerosis

Germany
Biogen

Recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB115

Healthy Volunteer | Muscular Atrophy, Spinal

Korea, Republic of, Germany, Belgium, Netherlands, France, Italy, Poland, Canada, United Kingdom, Israel
Biogen

Recruiting

Pediatric Spinal Muscular Atrophy (SMA) China Registry

Muscular Atrophy, Spinal

China
Biogen

Recruiting

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus (TOPAZ-1)

Lupus Erythematosus, Systemic

United States, Australia, Korea, Republic of, Chile, Spain, Poland, Philippines, Taiwan, Greece, Brazil, Bulgaria, Mexico, France, Russian Federation, Sweden
Biogen

Recruiting

A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation (ATLAS)

Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation

United States, Canada, Spain, Australia, Germany, Italy, Japan, Korea, Republic of, United Kingdom, Belgium, Brazil, France, Poland, Sweden
Biogen

Terminated

A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Japan
Biogen

Completed

A Study to Explore Association Patterns Between Digital Outcome Assessments From the Konectom™ Platform and Magnetic Resonance Imaging (MRI) Measures of Brain Tissue Damage

Multiple Sclerosis (MS)

Germany
Biogen

Active, not recruiting

A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy (NURTURE)

Spinal Muscular Atrophy

United States, Taiwan, Israel, Australia, Qatar, United Kingdom, Turkey, Italy, Germany, Argentina, Canada
Biogen

Active, not recruiting

A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China

Multiple Sclerosis

China
Biogen

Completed

Tysabri Observational Program (TOP)

Relapsing-Remitting Multiple Sclerosis

Belgium, Germany, Italy, Norway, France, Mexico, Australia, Spain, Portugal, Greece, Netherlands, United Kingdom, Czechia, Slovakia, Finland, Canada, Argentina, Brazil
Biogen

Completed

A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111 (GEMINI)

Choroideremia

United States, Germany, France
Biogen

Withdrawn

A Study to Evaluate the Efficacy and Safety of BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well (DAISY)

Ischemic Stroke
Biogen

Completed

A Study to Assess the Clinical Validity of Konectom™ in Adults Living With Neuromuscular Disorders (DigiNOA)

Spinal Muscular Atrophy

Germany
Biogen

Completed

A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder

Depressive Disorder, Major

United States
Biogen

Completed

A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)

Depressive Disorder, Major

United States
Biogen

Completed

Non-Interventional, Postmarketing Surveillance Study of Nusinersen Sodium Injection (PANDA)

Muscular Atrophy, Spinal

China
Biogen

Completed

A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder

Major Depression

United States
Biogen

Terminated

A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 Diabetes

Type 2 Diabetes | Chronic Kidney Disease
Biogen

Completed

Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera (Lympho-TEC)

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

France
Biogen

Completed

BIIB014 Effects on the Pharmacokinetics (PK) of Rosiglitazone, Warfarin, and Midazolam

Healthy

United Kingdom
Biogen

Completed

Safety and Tolerability of Repeat Courses of IM Alefacept

Chronic Plaque Psoriasis

United States, Germany, France, Canada, Austria, Denmark, Netherlands, Switzerland, United Kingdom
Biogen

Active, not recruiting

A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)

Multiple Sclerosis

United States
Biogen

Completed

A Study to Evaluate Safety, Tolerability, and Distribution of a Microdose of Radiolabeled BIIB067 (99mTc-MAG3-BIIB067) Co-administered With BIIB067 (Tofersen) to Healthy Adults

Healthy Volunteers

United States

3

Subscribe